XPO1 and cancer: In both mutant models, interestingly, a modest increase in sensitivity to SINE inhibition was observed at select doses, suggesting manipulation of molecular signaling pathways stemming from the E571 XPO1 mutation may make these cells more susceptible to this form of anti-cancer treatment.